Gastric cancer
Conditions
Interventions
Group A:Total gastrectomy
Group B:Proximal gastrectomy
Sponsors
The Sixth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with stage T2-3 proximal gastric adenocarcinoma located in the upper 1/3 of the stomach (including gastroesophageal junction adenocarcinoma type II/III) were clinically evaluated, and there were no patients with 4D, 5 and 6 lymph node metastases or distant metastases on imaging (CT/EUS, etc.). Imaging and clinical surgeons evaluate patients for whom radical resection is feasible; 2. Tumor size not more than 4 cm; 3. Male or female patients aged 18-75 years; 4. No history of other malignant tumors; 5. The cardiopulmonary, liver and kidney functions are basically normal, and the ECOG body condition score is 0-1; 6. The patients were followed up for more than 5 years or until death; 7. Informed consent of the patient has been signed.
Exclusion criteria
Exclusion criteria: 1. Gastric stump cancer; 2. Postoperative pathology confirmed stage T4 or IV (16LN metastasis or peritoneal exocytosis); 3. Borrmann III (tumor diameter > 8cm) or IV, or 1/3 of the stomach invaded by the tumor; 4. The number of lymph nodes dissected was less than 16; 5. Receiving neoadjuvant chemotherapy; 6. Multiple gastric cancers (>= 2 lesions); 7. Patients with R1/R2 resection confirmed by postoperative pathology; 8. Pregnant or lactating women; 9. Emergency operation; 10. Distant metastasis of liver, lung, bone, etc.; Or supraclavicular lymph nodes, pelvic floor or ovarian species, peritoneal dissemination; 11. Patients with other serious diseases, including cardiovascular, respiratory, renal, or liver diseases, with poorly controlled hypertension, diabetes mellitus; 12. Mental disorders or diseases; 13. Patients who had participated in or were participating in other clinical trials within 4 weeks prior to enrollment; 14. Patients who have undergone surgery and whose effects have not been resolved; 15. History of malignant tumors of the stomach or esophagus, including stromal tumors, sarcomas, lymphomas, and carcinoids; 16. Poor patient compliance or the investigator considered poor patient compliance; 17. In the opinion of some investigators, patients with other clinical or laboratory conditions should not participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year overall survival;5-year disease free survival;postoperative complication;postoperative quality of life; | — |
Countries
China
Contacts
Public ContactYang Zuli
The Sixth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed